Is This Melanoma?
The stakes are too high not to know.
In fact, over half of ambiguous cases were misdiagnosed by a panel of expert dermatopathologists.3
Even the most experienced dermatopathologists encounter situations in which a benign mole cannot be distinguished from a malignant melanoma by histopathology alone. Unlike other diagnoses, there are no standard protocols, making a difficult situation worse. Currently, the best option is histopathologic analysis.
Subjectivity is simply not an option when the consequences of misdiagnosis are so severe.
Early diagnosis is critical for long-term survival.
Only 10–15% of patients with advanced disease survive past 5 years.
With risks this high and misdiagnosis so common, it is no surprise
melanoma is the 2nd most litigated cancer type for medical malpractice.
And behind every misdiagnosis is a patient.
20-year-old white female with lesion on her right arm.
Initial diagnosis: Spitz Nevus.
Treatment recommendation: Typical follow-up, including annual skin examinations and monthly self-exams.4
Four years later, she presented with palpable mass under right arm.
LNB: Lymph node positive for malignant melanoma, Stage IIIA.
Treatment recommendation: Consider adjuvant RT and/or clinical trial or observation or interferon alfa.
Introducing Myriad myPath™ Melanoma
A unique molecular assay created specifically to assist physicians in differentiating malignant melanoma from otherwise benign nevi. By analyzing 23 genes, this assay provides objective, additive diagnostic information unavailable from any other method – information that can help physicians deliver a more confident diagnosis.
end the guesswork and get started with Myriad myPath™ Melanoma.